TP53 and cancer: We chose to particularly look at effect of three inhibitory treatments experimentally, i.e., BCL2 (B), Wip1 (W), and p53-MDM2 (N), and their combinations, as BCL2 is the common wild-type gene target in the eight distinct cancer cell lines, and Wip1 and p53-MDM2 are frequently altered gene targets.